Action Required: Password Reset on Next Login
As part of our recent security and system improvements, a password reset will be required the next time you log in. This applies to username/password users only; SSO users are not affected.
To reset your password, please visit the Reset Password page.
We appreciate your patience during this transition and are available to assist with any questions. For support, please call us at +1 650-552-4224 or email us at support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Dice Therapeutics Inc.
Headquarters: South San Francisco, CA, United States of America
Website: N/A
Year Founded: 2013
Status: Acquired
BioCentury | Jul 8, 2024
Deals
Via $3.2B Morphic deal, Lilly gets oral integrin to compete in Entyvio’s class
Small molecule program, now in Phase II, could challenge injectable blockbuster; joins IBD drug Omvoh in pharma’s immunology arsenal
BioCentury | Apr 22, 2024
Finance
Delisting biotechs take AIM at U.K. exchange
What three companies’ decisions to delist say about life on the London exchange for development-stage biotechs
BioCentury | Jan 4, 2024
Deals
Parsing premiums: 2023’s biopharma M&A deals
2023’s highest-premium takeouts and its top-value deal all came early, but 4Q was notable for its pace of $1B+ deals
BioCentury | Jan 4, 2024
Management Tracks
Lanthaler leaving Evotec as CEO
Plus: Morphic’s CEO Tipirneni returns and more from Kojin, Harvard, Star, Novavax, Entrada, Brii, Switch, SmartCella
BioCentury | Sep 20, 2023
Data Byte
Immunology companies acquired by pharmas in 2020-23
At least 13 immunology-focused biotechs have been acquired for ≥$1B since start of 2020, with three of the deals announced this year
BioCentury | Aug 30, 2023
Finance
IPO superstars
Back to School 2023: Six companies with NASDAQ IPOs since 2021 have more than doubled their market caps. Another four met the doubling mark via M&A
BioCentury | Jul 5, 2023
Finance
Deals drive XBI rebound in 2Q
Could the long-awaited recovery for biotech be signaling its start?
BioCentury | Jun 20, 2023
Deals
Despite IRA, Lilly’s Ricks finds path to value in Dice’s small molecules
$2.4B deal gives Lilly autoimmune programs that complement Taltz, and a platform to make more oral therapies
BioCentury | Oct 14, 2022
Finance
Oct. 13 Quick Takes: Epic $168M round for Glick’s Odyssey
Plus Dice raises $300M on back of data, Liu’s Prime Medicine seeking $1.6B valuation, and updates from VectivBio, CSPC, Relmada and more
BioCentury | Oct 12, 2022
Product Development
Oral therapy sees a new hopeful for immune diseases in Dice’s DC-806
The small molecule against IL-17 could bring competition to TYK2 inhibitors
Items per page:
1 - 10 of 13